242 results on '"Morley, Nicholas"'
Search Results
2. Optical contrast amplification for enhancing event-based vision
3. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
4. Introduction to the Directed Energy for Aerospace Applications Virtual Collection
5. Reduced spatiotemporal bandwidth of motion stabilized event-based imaging sensors: experimental demonstration
6. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
7. Impact of formaldehyde, acetaldehyde, and N-(3-(Dimethylamino)propyl)methacrylamide on the efficacy of the human derived coagulation factor IX
8. Bone and Soft Tissue Tumors
9. Final Results from UKALL60+ (NCT01616238), a UK National Cancer Research Institute Trial for Older People with De Novo Acute Lymphoblastic Leukaemia
10. PET-CT scan timing after radical treatment for oropharyngeal squamous-cell carcinoma at Velindre: Adherence to NICE guidelines
11. FDG PET-CT for response-adapted radiotherapy planning in HPV+ oropharyngeal SCC: Initial experience from the PEARL trial
12. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
13. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial
14. CLEARED SARS-COV-2 INFECTION IS ASSOCIATED WITH LOWER RISK PULMONARY EMBOLISM
15. Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
16. Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial
17. Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)
18. Isolated splenic sarcoidosis: a rare cause of hypercalcaemia in a patient with type 1 diabetes
19. 18FDG PET-CT in sporadic Creutzfeldt-Jakob disease, correlated with MRI and histology
20. Supervised Machine Learning Approach to Identify Early Predictors of Poor Outcome in Patients with COVID-19 Presenting to a Large Quaternary Care Hospital in New York City
21. Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant
22. Bone and Soft Tissue Tumors
23. Imaging Evaluation of Musculoskeletal Tumors
24. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial
25. Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
26. Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
27. Molecular targeting for clinical cancer imaging
28. An analysis framework for event-based sensor performance
29. Durability of complete response after blinatumomab therapy for relapsed/refractory diffuse large B-cell lymphoma
30. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
31. Motion analysis of event-based sensors
32. A Competitive Approach to an Active Exhaust Heat Recovery System Solution
33. Innovative Passive Exhaust Valve Improves Sound Quality and Reduces Muffler Volume without Backpressure Penalty
34. Eyeball camera based calibration and performance verification for spatial computing systems
35. Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma
36. Genetic and Genomic Characterisation of Older Adults with Acute Lymphoblastic Leukemia Treated on the UKALL14 and UKALL60+ Clinical Trials
37. Indolent T-Cell Lymphoproliferative Disorder of the Uterine Corpus: A Case Report
38. Withdrawal Symptoms From E-Cigarette Abstinence Among Adult Never-Smokers: A Pilot Experimental Study
39. Withdrawal Symptoms From E-Cigarette Abstinence Among Former Smokers: A Pre–Post Clinical Trial
40. Effectiveness of switching to very low nicotine content cigarettes plus nicotine patch versus reducing daily cigarette consumption plus nicotine patch to decrease dependence: an exploratory randomized trial
41. Nitrogen availability alters rhizosphere processes mediating soil organic matter mineralisation
42. Aerobic denitrification in soils : fact or fiction?
43. Indolent T-Cell Lymphoproliferative Disorder of the Uterine Corpus: A Case Report
44. Durability of complete response after blinatumomab therapy for refractory/relapsed aggressive B-cell non-Hodgkin lymphoma.
45. Tracking from a moving platform with the Dynamic Vision Sensor
46. Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
47. Analysis of event-based sensor system performance with moving object detection tasks
48. Optical contrast amplification for enhancing event-based vision
49. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial
50. Complex controls on nitrous oxide flux across a large-elevation gradient in the tropical Peruvian Andes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.